Develops immunotherapies for autoimmune diseases and inflammatory conditions, focusing on modulating immune responses through biologic therapeutics.
Kineta, Inc., a clinical stage biotechnology company, specializes in the development of immunotherapies across oncology, neuroscience, and biodefense domains. Serving a diverse clientele including private, government, and industry partners, Kineta is recognized for its innovative approaches in addressing significant medical challenges.
Established in 2007 and originally known as Lecura, Inc., Kineta has forged strategic partnerships with leading entities such as Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. These collaborations underscore Kineta's commitment to advancing groundbreaking therapies through collective expertise and resources.
Headquartered in Seattle, Washington, Kineta continues to drive scientific discovery and therapeutic development in pursuit of transformative treatments for complex diseases. The company's research initiatives aim to enhance patient outcomes and shape the future of immunotherapy across multiple therapeutic areas.